Adaptive Phase I & II Trials

Rapid approval, flexible conduct, adaptive protocols in a MHRA accredited facility.

View service

Phase III Clinical Studies

Fast and efficient patient recruitment for Phase III clinical trials.

View service

TQT Studies

Cardiac safety assessments are built into every clinical study.

View service

Bridging Studies

Fast track your global marketing authorisations with our ethnic bridging studies.

View service

Patient Recruitment

Fast and efficient in-house team, specialising in patient recruitment.

View service

Data Management

Flexible, efficient and tailored to our clients’ needs.

View service

Gene Editing & Gene Silencing

Richmond Pharmacology is at the forefront of gene editing.

View service

Latest news

Von Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

First patient enrolled in telehealth study, the Pathway Study

February 25, 2025
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event